Oncology Pharma (OTCMKTS:ONPH) vs. VTEX (NYSE:VTEX) Financial Comparison

Oncology Pharma (OTCMKTS:ONPH) and VTEX (NYSE:VTEX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Volatility and Risk

Oncology Pharma has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, VTEX has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.

Institutional & Insider Ownership

63.7% of VTEX shares are owned by institutional investors. 18.0% of Oncology Pharma shares are owned by company insiders. Comparatively, 40.9% of VTEX shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Oncology Pharma and VTEX”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Pharma	N/A	N/A	N/A	N/A	N/A
VTEX	$201.52 million	6.30	-$13.69 million	$0.03	230.08

Oncology Pharma has higher earnings, but lower revenue than VTEX.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Oncology Pharma and VTEX, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Pharma	0	0	0	0	N/A
VTEX	0	0	5	0	3.00

VTEX has a consensus target price of $10.40, suggesting a potential upside of 50.72%. Given VTEX’s higher possible upside, analysts plainly believe VTEX is more favorable than Oncology Pharma.

Profitability

This table compares Oncology Pharma and VTEX’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Pharma	N/A	N/A	N/A
VTEX	1.51%	1.36%	0.97%

Summary

VTEX beats Oncology Pharma on 9 of the 9 factors compared between the two stocks.

About Oncology Pharma

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.

About VTEX

VTEX provides software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce strategy, including building online stores, integrating, and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It has operations in Brazil, Argentina, Chile, Colombia, France, Italy, Mexico, Peru, Portugal, Romania, Singapore, Spain, the United Kingdom, and the United States. VTEX was founded in 2000 and is headquartered in London, the United Kingdom.